GSK Reports 61% Response Rate for Ris—Rez in Early Lung Cancer Study

GSK said the drug produced a 61% response rate at the higher dose in a Phase Ib study, compared with 32% at the lower dose. The results will be presented at ESMO 2026 and support use of the higher dose in an ongoing global Phase III trial.